PRETECT™ Platform

nibrozetone (RRx-001)

Onco PRETECT · Neuro PRETECT · Gyn PRETECT
View Publications
orange line and dot

PRETECT combines the words pretreatment, and protection, for supportive care and inflammatory conditions.

EpicentRx designed the first-in-class anti-inflammatory and antioxidant small molecule, RRx-001, with “pretection” in mind through inhibition of the NLRP3 inflammasome. RRx-001 is a disease-modifying intervention that protects normal tissues from the side effects of other therapies when administered as a pretreatment. RRx-001 has been awarded Fast Track designation for the treatment of severe oral mucositis in head and neck cancer.

TONY REID, M.D. Ph.D.

Chief Executive Officer & Chief Scientific Office

BIO

FRANCK BRINKHAUS, Ph.D.

Chief Financial Officer

BIO

BRYAN ORONSKY, M.D. Ph.D.

Chief Medical Officer

BIO

CHRIS LARSON,
M.D. Ph.D.
Vice President of Viral Therapy

BIO

MEAGHAN STIRN,
M.B.A
Controller & VP of Special Projects

BIO

SCOTT CAROEN
Senior Director of Operations & Corporate Development

BIO

Rajan Kumar
ESQ
Chief Executive Officer & Chief Scientific Office

BIO

Control inflammation & control the disease

RRx-001 inhibits the inflammasome

The Inflammasome is responsible for activation of inflammatory responses. With chronic inflammation tissue destruction that occurs outpaces the regeneration of damaged tissues. Eventually, over time, the normal function of these tissues is reduced or lost. In chronically inflamed tissues, which may result from unresolved sources of foreign bodies, irritants or infections, the inflammasome fuels an inflammatory response for weeks to months or even years, resulting in a range of metabolic, neurological, autoimmune disorders as well as in the initiation of cancer.
The Answer: AdAPT-001 programs infected cancer cells to produce a TGFβ “trap” molecule that is designed to neutralize TGFβ within the infected tumor. Eliminating the t-cell silencing TGFβ protein allows for the immune system to remain activated against cancer, making AdAPT-001 unlike any other immunotherapy.
AdAPT-001 doesn’t just create a cancer targeted infection, it produces a proprietary TGFβ “trap” protein to eliminate this tumor defense mechanism and allow for sustained immune response against cancer – alone or in combination with immune checkpoint inhibitors.

TONY REID, M.D. Ph.D.

Chief Executive Officer & Chief Scientific Office

BIO

FRANCK BRINKHAUS, Ph.D.

Chief Financial Officer

BIO

BRYAN ORONSKY, M.D. Ph.D.

Chief Medical Officer

BIO

CHRIS LARSON,
M.D. Ph.D.
Vice President of Viral Therapy

BIO

MEAGHAN STIRN,
M.B.A
Controller & VP of Special Projects

BIO

SCOTT CAROEN
Senior Director of Operations & Corporate Development

BIO

Rajan Kumar
ESQ
Chief Executive Officer & Chief Scientific Office

BIO

Control inflammation & control the disease

RRx-001 inhibits the inflammasome

The Inflammasome is responsible for activation of inflammatory responses. With chronic inflammation tissue destruction that occurs outpaces the regeneration of damaged tissues. Eventually, over time, the normal function of these tissues is reduced or lost. In chronically inflamed tissues, which may result from unresolved sources of foreign bodies, irritants or infections, the inflammasome fuels an inflammatory response for weeks to months or even years, resulting in a range of metabolic, neurological, autoimmune disorders as well as in the initiation of cancer.
The Answer: AdAPT-001 programs infected cancer cells to produce a TGFβ “trap” molecule that is designed to neutralize TGFβ within the infected tumor. Eliminating the t-cell silencing TGFβ protein allows for the immune system to remain activated against cancer, making AdAPT-001 unlike any other immunotherapy.
AdAPT-001 doesn’t just create a cancer targeted infection, it produces a proprietary TGFβ “trap” protein to eliminate this tumor defense mechanism and allow for sustained immune response against cancer – alone or in combination with immune checkpoint inhibitors.

SUSAN KNOX, M.D.
Associate Professor of Radiation Oncology, Emerita, Stanford University

Stanford Hospital and Clinics, Lucile Packard Children’s Hospital

THEODORE LAWRENCE, M.D., Ph.D.
Chair of the Department of Radiation Oncology, University of Michigan

Isadore Lampe Professor of Radiation Oncology

KENNETH C. ANDERSON, M.D.
Kraft Family Professor of Medicine, Medicine, Harvard Medical School

Physician, Oncology, Brigham And Women’s Hospital

SUSAN KNOX, M.D.
Associate Professor of Radiation Oncology, Emerita, Stanford University

Stanford Hospital and Clinics, Lucile Packard Children’s Hospital

THEODORE LAWRENCE, M.D., Ph.D.
Chair of the Department of Radiation Oncology, University of Michigan

Isadore Lampe Professor of Radiation Oncology

KENNETH C. ANDERSON, M.D.
Kraft Family Professor of Medicine, Medicine, Harvard Medical School

Physician, Oncology, Brigham And Women’s Hospital

Neuro PRETECT (grant funded)

RRx-001 (nibrozetone) is a multitargeted neuroprotector that crosses the blood brain barrier (BBB) and defends the CNS against several of the pathological hallmarks that are common to chronic neurodegenerative disorders.
EpicentRx, in collaboration with Dr. Richard Gordon, renowned neuroinflammation expert from Brisbane, Australia, has also been awarded several grants to study RRx-001 in ALS/MND, CNS toxicities and other related conditions.
Neurodegenerative Studies Backed by Grant Funding

Parkinson’s

MJFF Therapeutic Pipeline & DoD PRP

ALS

FightMND Drug Discovery Program Funded

Alzheimer’s & Traumatic Brain Injury

(Pilot Preclinical)

Neurotoxicity

DoD CDMRP Translational Award

Gyn PRETECT (clinical grant funded)

A phase 2 clinical trial with RRx-001 in endometriosis, a chronic inflammatory gynecological condition, is underway at the University of Edinburgh, in collaboration with the University of Warwick in the U.K.

The Future Starts Today

Contact us
SUSAN KNOX, M.D.
Associate Professor of Radiation Oncology, Emerita, Stanford University

Stanford Hospital and Clinics, Lucile Packard Children’s Hospital

THEODORE LAWRENCE, M.D., Ph.D.
Chair of the Department of Radiation Oncology, University of Michigan

Isadore Lampe Professor of Radiation Oncology

KENNETH C. ANDERSON, M.D.
Kraft Family Professor of Medicine, Medicine, Harvard Medical School

Physician, Oncology, Brigham And Women’s Hospital

SUSAN KNOX, M.D.
Associate Professor of Radiation Oncology, Emerita, Stanford University

Stanford Hospital and Clinics, Lucile Packard Children’s Hospital

THEODORE LAWRENCE, M.D., Ph.D.
Chair of the Department of Radiation Oncology, University of Michigan

Isadore Lampe Professor of Radiation Oncology

KENNETH C. ANDERSON, M.D.
Kraft Family Professor of Medicine, Medicine, Harvard Medical School

Physician, Oncology, Brigham And Women’s Hospital